Myomo (MYO) Amortization of Deferred Charges (2020 - 2021)
Myomo (MYO) reported Amortization of Deferred Charges of -$99947.0 for Q2 2021, down 349.87% on a YoY basis from $40000.0 in Q2 2020, and down 159.99% quarter-over-quarter from $166600.0 in Q1 2021.
Myomo (MYO) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Myomo has reported Amortization of Deferred Charges for 2 years, with the latest figure at -$99947.0 in Q2 2021.
- For the quarter ending Q2 2021, Amortization of Deferred Charges fell 349.87% year-over-year to -$99947.0; the trailing twelve-month figure through Jun 2021 stood at $78753.0 (down 26.49% YoY), and the FY2020 full-year result was $161869.0, up 177.67% from the prior year.
- Amortization of Deferred Charges for Q2 2021 stood at -$99947.0, down from $166600.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $166600.0 in Q1 2021, with the low at -$99947.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Myomo | 49.44 Mn | 31.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -99,947.00 |
| Jun 30, 2021 | -99,947.00 |
| Mar 31, 2021 | 166,600.00 |
| Mar 31, 2021 | 166,600.00 |
| Sep 30, 2020 | 12,100.00 |
| Sep 30, 2020 | 12,100.00 |
| Jun 30, 2020 | 40,000.00 |
| Jun 30, 2020 | 40,000.00 |
| Mar 31, 2020 | 67,132.00 |
| Mar 31, 2020 | 67,132.00 |